Tozorakimab Drug Asset Due Diligence Report 2026

This Tozorakimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tozorakimab can convert its Monoclonal antibody profile and IL-33 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tozorakimab (query alias: tozorakimab)
Modality / target	Monoclonal antibody; IL-33; IL-33 inhibitors
Highest global status	NDA/BLA
Originator	MedImmune LLC
Active developers	AstraZeneca AB, AstraZeneca PLC, AstraZeneca Global R&D (China) Co., Ltd.

The MCP disease footprint includes Acute respiratory infections, Infectious Lung Disorder, Pneumovirus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07566195	Phase 3	Recruiting	60	Adverse events
NCT06890351	Phase 2	Not yet recruiting	540	Annualised rate of severe asthma exacerbations
NCT06897748	Phase 2	Completed	98	Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data From the FRONTIER Phase 2 Program of 1076 Patients

Phase 2; n=1076; evaluation: Positive. Reported fields: Adverse Event: Deaths = Deaths were only reported in one study (FRONTIER-1 [DKD]) and occurred in similar proportions for both tozorakimab and placebo. No deaths were attributed to tozorakimab. ; Adverse Event: Deaths = Deaths were only reported in one study (FRONTIER-1 [DKD]) and occurred in similar proportions for both tozorakimab and placebo. No deaths were attributed to tozorakimab.

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)

Phase 2; n=137; evaluation: not stated. Reported fields: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic(Least Squares Mean) = -0.005 Litre (Standard Error, 0.025); Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic(Least Squares Mean): LS Mean Difference = 0.024(80% CI, -0.015 to 0.063), P-Value = 0.216; Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic(Least Squares Mean) = 0.019 Litre (Standard Error, 0.026)

阿斯利康再败“慢阻肺”

临床2期; n=not disclosed; evaluation: 不佳. Reported fields: FEV = 59 mL ; FEV = NR

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tozorakimab addresses Acute respiratory infections, Infectious Lung Disorder, Pneumovirus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-33 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-10-28	Qyuns Therapeutics Partners with Roche for Global Development of QX031N	Preclinical	US$75.0M upfront; US$995.0M milestones
2019-06-21	Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method of selecting patients for treatment with an il-33 axis antagonist”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO